Mesoblast (MESO) Receiving Somewhat Favorable News Coverage, Study Shows
News coverage about Mesoblast (NASDAQ:MESO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mesoblast earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.258265871915 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Wired News – TiGenix Received an Exclusive Global Patent License to Cx601 from Mesoblast in the Local Treatment of Fistulae (finance.yahoo.com)
- Maxim Group Analysts Give Mesoblast (MESO) a $14.00 Price Target (americanbankingnews.com)
- Mesoblast Limited (MESO) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Ionis Pharmaceuticals (IONS) & Mesoblast (MESO) Head to Head Review (americanbankingnews.com)
- Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the … – GlobeNewswire (press release) (globenewswire.com)
A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Mesoblast in a research note on Wednesday, August 23rd. Maxim Group set a $14.00 price objective on Mesoblast and gave the company a “buy” rating in a research note on Wednesday, August 30th. CIBC assumed coverage on Mesoblast in a research note on Thursday, August 31st. They set an “outperform” rating and a $16.00 price objective on the stock. Oppenheimer assumed coverage on Mesoblast in a research note on Thursday, August 31st. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, Zacks Investment Research upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Wednesday, October 4th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Mesoblast presently has an average rating of “Hold” and a consensus target price of $13.14.
ILLEGAL ACTIVITY WARNING: “Mesoblast (MESO) Receiving Somewhat Favorable News Coverage, Study Shows” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/mesoblast-meso-receiving-somewhat-favorable-news-coverage-study-shows/1772164.html.
Mesoblast Company Profile
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.